NCT00291733

Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease

Levetiracetam Administration for the Management of Levodopa-Induced Dyskinesias in Parkinson's Disease: A Double-Blind,Placebo-Controlled, Crossover Trial

• Status: Unknown
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 50 (estimated)
• Sponsor: 1st Hospital of Social Security Services · Academic / Other
• Sex: All
• Age: 30 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

Levodopa-induced dyskinesias have been associated with irregular oscillatory discharge characteristics of basal ganglia. From the other hand, LEV which shares a different electrophysiologic profile than other antiepileptics, inhibits hyper-synchronization of abnormal neuronal firing in experimental models of epilepsy. LEV also reduces levodopa-induced dyskinesias in MPTP-lesioned macaques and modulates "priming phenomenon" which associated with long-term changes in synaptic function that can lead to dyskinesias in PD. Study objectives : * To evaluate the effects of levetiracetam (LEV) in two doses (500 and 1000mg) vs placebo on disabling dyskinesias that develop as result of long-term treatment with levodopa, occurring at the time of maximal clinical improvement in patients with Parkinson's disease (PD). * To evaluate the safety of LEV in patients with PD and antiparkinsonian medication.

Conditions

• Levodopa Induced Dyskinesia

Interventions

Type	Name	Description
DRUG	Levetiracetam	500mg (2 tabl of 250) for one week and 1000mg (4 tabl of 250) for one week
DRUG	Placebo	Placebo tabl

Timeline

• Start date: 2006-05-01
• Completion: 2007-10-01
• First posted: 2006-02-15
• Last updated: 2007-11-15

Locations

1 site across 1 country: Greece